Skip to content
DataLookout
Menu

NCT07938619

Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Complete response rate (CRR)
Timeframe: Up to 12 cycles ( each cycle is 28 days)

Secondary (9)

Objective response rate (ORR)
Disease control rate (DCR)
Duration of Response (DoR)
Duration of Complete Response (DoCR)
Progression-free survival (PFS)
Show 4 moreShow less
Overall survival (OS)
Time to Response (TTR)
Adverse events
Change in Quality of Life

Arms and interventions

Tafasitamab in combination with Lenalidomide, Rituximab and OrelabrutinibExperimental

Participants will receive tafasitamab in combination with lenalidomide, rituximab and orelabrutinib for 4 cycles, and then receive tafasitamab and lenalidomide for additional 8 cycles. Each treatment cycle is 28 days.

Drugs: Tafasitamab, Lenalidomide, Rituximab, Orelabrutinib

Sites

3 sites in 1 country